Long‐Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM‐EZ Study
Authors:
- Peter L SelbyPSPeter L Selby
- Stuart H RalstonSRStuart H Ralston
- for the PRISM‐EZ Trial GroupFGfor the PRISM‐EZ Trial Group
- 8 February 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 32 (6) , 1165-1173
Abstract
It has been suggested that normalization of bone turnover may improve clinical outcome in Paget's disease of bone (PDB) by preventing complications such as fractures and the development of osteoarthritis. Here we investigated the long‐term effects of a treatment strategy that aimed to normalize bone turnover in PDB with that of symptomatic treatment. The study group comprised 502 subjects who were enrolled into a 3‐year extension of the Paget's Disease: Randomized Trial of Intensive versus Symptomatic Management (PRISM) study. Intensive bisphosphonate therapy was continued in 270 of these subjects with the aim of normalizing bone turnover using zoledronic acid as the treatment of first choice. Symptomatic treatment continued in 232 subjects in whom bisphosphonates were only given for the treatment of bone pain. The primary outcome was fracture and secondary outcomes were orthopedic procedures, quality of life, and bone pain, adjusted for baseline characteristics. Serum total alkaline phosphatase (ALP) concentrations were significantly lower in the intensive group on entry to the study and the differences between groups increased as the study progressed. There were no clinically important differences in quality of life measures or bone pain between the treatment groups. Intensive treatment was associated with a nonsignificant increase in fracture risk (hazard ratio = 1.90; 95% CI, 0.91 to 3.98; p = 0.087), orthopedic procedures (1.81; 95% CI, 0.71 to 4.61; p = 0.214), and serious adverse events (relative risk 1.28; 95% CI, 0.96 to 1.42). We conclude that long‐term intensive bisphosphonate therapy confers no clinical benefit over symptomatic therapy and is associated with a nonsignificant increase in the risk of fractures, orthopedic events, and serious adverse events. The results of this study suggest that in patients with established PDB, bisphosphonate therapy should focus on control of symptoms rather than suppression of bone turnover. © 2016 American Society for Bone and Mineral Research.Keywords
Funding Information
- Arthritis Research UK (42014)
This publication has 22 references indexed in Scilit:
- Letter to the Editor: The Endocrine Society Clinical Practice Guidelines on Paget's Disease: Many Recommendations Are Not Evidence BasedThe Journal of Clinical Endocrinology & Metabolism, 2015
- Paget's Disease of BoneNew England Journal of Medicine, 2013
- Clinical Determinants of Quality of Life in Paget’s Disease of BoneCalcified Tissue International, 2007
- Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and RisedronateJournal of Bone and Mineral Research, 2007
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseNew England Journal of Medicine, 2005
- Guidelines on the management of Paget’s disease of bone*Bone, 2002
- Incidence and Natural History of Paget's Disease of Bone in England and WalesJournal of Bone and Mineral Research, 2002
- A Clinical Approach to Diagnosis and Management of Paget's Disease of BoneJournal of Bone and Mineral Research, 2001
- A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of boneThe American Journal of Medicine, 1999
- Paget's disease of bone and quality of lifeJournal of Bone and Mineral Research, 1996